Exchange Traded Concepts LLC Purchases 1,233 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Exchange Traded Concepts LLC grew its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 21.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,890 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,233 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Jazz Pharmaceuticals were worth $768,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in JAZZ. Capital World Investors acquired a new stake in Jazz Pharmaceuticals in the first quarter valued at $171,943,000. Swedbank AB acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at about $106,936,000. Rubric Capital Management LP acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at about $65,812,000. Pacer Advisors Inc. raised its position in shares of Jazz Pharmaceuticals by 40.7% during the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after acquiring an additional 527,187 shares during the last quarter. Finally, Baupost Group LLC MA lifted its stake in shares of Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after acquiring an additional 440,552 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $115.04 on Friday. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. The firm has a fifty day simple moving average of $110.88 and a two-hundred day simple moving average of $109.79. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $137.38. The firm has a market capitalization of $7.25 billion, a PE ratio of 23.72, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. Analysts forecast that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

JAZZ has been the subject of several analyst reports. Morgan Stanley lowered their price target on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a report on Friday, July 12th. Robert W. Baird lowered their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. Wells Fargo & Company cut their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Finally, JPMorgan Chase & Co. boosted their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $173.14.

Insider Activity

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.